



Defense Health Agency J-7 Continuing Education Program Office

MAMC Pharmacy Series: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for the Pharmacist

Asynchronous/Home Study, June 12, 2026 – December 12, 2026

Continuing Education (CE)/Continuing Medical Education (CME) Information

This CE/CME activity is accredited by the DHA J-7 Continuing Education Program Office (CEPO). This activity provides continuing education for pharmacists and pharmacy technicians across the Military Health System (MHS). A certificate of attendance is available for other attendees.

MAMC Pharmacy Series: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for the Pharmacist (1.00 clock hour)

Learning Objectives:

1. Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature.
2. Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk.
3. Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis.
4. Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis.
5. Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide.
6. Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease.

Faculty:

Emily Leaf, PharmD, BC-ADM. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

Terri Foster, PharmD, MA, CDCES. Presenter has no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

Disclosures:

DHA J-7 staff, planners, authors, faculty, and content reviewers for this educational activity have no relevant financial or non-financial relationship(s) with ineligible companies to disclose.

Pharmacists (ACPE)



UAN JA4008136-0000-26-093-H01-P

No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge based activity will provide a maximum of 1.00 contact hour of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Pharmacy Technicians (ACPE)



UAN JA4008136-0000-26-093-H01-T

No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge based activity will provide a maximum of 1.00 contact hour of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Other Professionals

All other healthcare professionals completing this CE/CME activity will be issued a Certificate of Attendance indicating participation and the number of hours of CE/CME credit. This may be used for submission to licensing boards for satisfaction of CE/CME requirements.

Commercial Support:

No commercial support was provided for this activity.

Participation Costs:

There is no cost to participate in this activity.

CE/CME Inquiries:

For all CE/CME related inquiries, please contact: dha.ncr.j7.mbx.continuing-education-office@health.mil.

How to Obtain CE/CME Credit:

To receive CE/CME credit, you must complete the program posttest(s) and evaluation(s) before collecting your certificate(s). The posttests and evaluations will be available through 12 December 2026 at 2359 ET at the following URL: www.dhaj7-cepo.com.